Marshall Wace LLP Acquires 579,103 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Marshall Wace LLP increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 165.2% during the 4th quarter, HoldingsChannel reports. The firm owned 929,744 shares of the company’s stock after purchasing an additional 579,103 shares during the period. Marshall Wace LLP’s holdings in Harmony Biosciences were worth $31,992,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of HRMY. GAMMA Investing LLC boosted its holdings in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after buying an additional 436 shares during the period. Mendota Financial Group LLC increased its holdings in Harmony Biosciences by 24,125.0% during the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after purchasing an additional 965 shares in the last quarter. KBC Group NV raised its stake in shares of Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after purchasing an additional 819 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock valued at $80,000 after purchasing an additional 519 shares in the last quarter. Finally, Summit Investment Advisors Inc. boosted its position in shares of Harmony Biosciences by 34.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company’s stock worth $137,000 after buying an additional 1,029 shares during the period. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY opened at $28.46 on Friday. Harmony Biosciences Holdings, Inc. has a 12 month low of $26.47 and a 12 month high of $41.61. The stock has a 50 day moving average of $32.92 and a 200-day moving average of $34.46. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.63 billion, a P/E ratio of 13.49, a P/E/G ratio of 0.47 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. During the same period in the prior year, the firm earned $0.45 earnings per share. The company’s revenue was up 19.5% on a year-over-year basis. As a group, equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Insider Transactions at Harmony Biosciences

In related news, CFO Sandip Kapadia sold 25,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The disclosure for this sale can be found here. Insiders sold a total of 61,945 shares of company stock worth $2,442,815 over the last quarter. Company insiders own 30.80% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on HRMY. Needham & Company LLC restated a “buy” rating and issued a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 8th. Mizuho lifted their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a research note on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They set a “buy” rating and a $55.00 price objective for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $53.33.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.